SignatureFD’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$80.4K Buy
1,365
+68
+5% +$4.15K ﹤0.01% 1674
2026
Q2
$73.7K Sell
1,297
-256
-16% -$11.4K ﹤0.01% 1634
2026
Q1
$46.1K Hold
1,553
– – ﹤0.01% 1777
2025
Q4
$59.3K Sell
1,553
-153
-9% -$4.98K ﹤0.01% 1550
2025
Q3
$40.8K Hold
1,706
– – ﹤0.01% 1743
2025
Q2
$25.2K Hold
1,706
– – ﹤0.01% 1938
2025
Q1
$30.6K Hold
1,706
– – ﹤0.01% 1837
2024
Q4
$29.7K Sell
1,706
-65
-4% -$1.15K ﹤0.01% 1858
2024
Q3
$24.8K Buy
1,771
+166
+10% +$1.73K ﹤0.01% 1937
2024
Q2
$13.2K Sell
1,605
-1,452
-47% -$9.8K ﹤0.01% 2154
2024
Q1
$23.6K Buy
3,057
+36
+1% +$304 ﹤0.01% 1916
2023
Q4
$27.2K Buy
3,021
+2,849
+1,656% +$20.7K ﹤0.01% 1773
2023
Q3
$1.54K Sell
172
-371
-68% -$5.24K ﹤0.01% 2843
2023
Q2
$8.34K Buy
543
+359
+195% +$6.53K ﹤0.01% 2318
2023
Q1
$4.14K Buy
+184
New +$3.91K ﹤0.01% 2582
2022
Q4
– Sell
-18
Closed – – 3409
2022
Q3
$0 Buy
+18
New +$465 ﹤0.01% 3358
2019
Q4
– Sell
-40
Closed – – 2273
2019
Q3
$0 Hold
40
– – ﹤0.01% 2205
2019
Q2
$1K Buy
+40
New +$790 ﹤0.01% 1955

Other funds holding TVTX

SignatureFD's TVTX Position: Q3 2026 in Review

SignatureFD increased its Travere Therapeutics (TVTX) stake by 5.2% in Q3 2026, buying an estimated $4.15K and bringing the position to 1,365 shares worth $80.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

SignatureFD first reported a position in TVTX in Q2 2019 and has held it in 18 quarters since. 341 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • SignatureFD held 1,365 shares of Travere Therapeutics worth $80.4K as of Q3 2026.
  • SignatureFD bought 68 Travere Therapeutics shares in Q3 2026, an estimated $4.15K.
  • Travere Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #1674 holding.
  • SignatureFD first reported a position in Travere Therapeutics in Q2 2019 and has held it in 18 quarters since.
  • 341 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.